Shikari® (S-ATAV) Anti-Avelumab ELISA

Enzyme immunoassay for the quantitative determination of Bevacizumab (Avastin®) in human serum and plasma

This kit has been especially developed for the quantitative determination of Bevacizumab in serum and plasma samples between the Cmin and Cmax range of concentrations.

Bevacizumab Drug Bank Accession Number is DB00112 

Bevacizumab is a monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.

There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.It is a humanized monoclonal IgG antibody, and inhibits angiogenesis by binding and neutralizing VEGF-A. Bevacizumab is generally indicated for use in combination with different chemotherapy regimens which are specific to the type, severity, and stage of cancer. Measurement of biological drug trough levels and antibody to biological drug gained high importance during the course of treatment. These measurements enable dose adjustments and switch to another class of biological drug when necessary.

All SHIKARI® ELISA kits are suitable for biosimilar work.